ALDX:NSD-Aldeyra The (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.93

Change

-0.06 (-1.50)%

Market Cap

USD 0.23B

Volume

0.64M

Avg Analyst Target

USD 20.50 (+421.63%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALDX Stock Forecast & Price:
Based on the Aldeyra The stock forecasts from 4 analysts, the average analyst target price for Aldeyra The is USD 20.50 over the next 12 months. Aldeyra The’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aldeyra The is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aldeyra The’s stock price was USD 3.93. Aldeyra The’s stock price has changed by +23.97% over the past week, +26.77% over the past month and -65.56% over the last year.

About Aldeyra The (ALDX:NSD)

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for t ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+4.18 (+1.51%)

USD73.48B 30.32 20.19
REGN Regeneron Pharmaceuticals Inc

+3.20 (+0.54%)

USD66.17B 8.57 6.35
MRNA Moderna Inc

+0.62 (+0.44%)

USD57.82B 4.27 2.57
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.59 (+0.33%)

USD32.85B 55.02 44.86
BNTX BioNTech SE

+2.16 (+1.54%)

USD32.57B 2.40 1.28
RPRX Royalty Pharma Plc

-0.47 (-1.10%)

USD28.87B 31.29 15.41
GMAB Genmab AS

+0.32 (+1.02%)

USD21.17B 63.61 5.25
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx NV ADR

+9.11 (+2.50%)

USD20.26B N/A -30.89

ETFs Containing ALDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.75% 89% B+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.75% 89% B+ 76% C
Trailing 12 Months  
Capital Gain -65.31% 50% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.31% 50% F 27% F
Trailing 5 Years  
Capital Gain -15.48% 68% D+ 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.48% 67% D+ 33% F
Average Annual (5 Year Horizon)  
Capital Gain 24.16% 72% C- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.16% 71% C- 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 100.86% 23% F 13% F
Risk Adjusted Return 23.95% 67% D+ 56% F
Market Capitalization 0.23B 62% D- 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.18 63% D 65% D
Price / Cash Flow Ratio -0.01 10% F 49% F
EV/EBITDA 0.25 65% D 88% B+
Management Effectiveness  
Return on Equity -39.95% 68% D+ 27% F
Return on Invested Capital -38.01% 67% D+ 25% F
Return on Assets -20.90% 63% D 20% F
Debt to Equity Ratio 7.54% 68% D+ 76% C
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.47 52% F 35% F
Short Percent 7.17% 37% F 26% F
Beta 1.64 34% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector